Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million
October 24 2016 - 6:28AM
As previously announced on October 24 2016 Oasmia
has acquired a novel cancer project which was paid for by
3,080,000 newly issued shares at a share price of approximately SEK
8.12 per share
In order to enable the transaction, the Board of Directors of
Oasmia has, pursuant to the authorization granted by the annual
general meeting held on September 26, 2016, resolved on a directed
issue of 3,080,000 new shares.
Through the issue, the number of shares in Oasmia increases by
3,080,000 from 115,959,310 to 119,039,310 and the share capital
increases by SEK 308,000 from SEK 11,595,931 to SEK 11,903,931. The
new issue results in an equity dilution of approximately 2.6
percent after the issue is completed.
The information above has been made public in accordance with
the Securities Market Act and the Financial Instruments Trading
Act.
Notes to editors:
About Oasmia Pharmaceutical AB Oasmia
Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology.
The company's product development aims to create and manufacture
novel nanoparticle formulations and drug-delivery systems based on
well-established cytostatics which, in comparison with current
alternatives, show improved properties, reduced side-effects, and
expanded applications. The company's product development is based
on its proprietary in-house research and company patents. Oasmia is
listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock
Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm
(OASM.ST).
IMPORTANT INFORMATION Issuance, publication or distribution of
this press release in certain jurisdictions could be subject to
restrictions. The recipient of this press release is responsible
for using this press release and the constituent information in
accordance with the rules and regulations prevailing in the
particular jurisdiction. This press release does not constitute an
offer or an offering to acquire or subscribe for any Oasmia
Pharmaceutical AB (publ) securities in any jurisdiction, neither
from Oasmia Pharmaceutical AB (publ) nor anyone else.
Julian Aleksov Tel: +46 18 50 54 40 E-mail:
julian.aleksov@oasmia.com
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Apr 2024 to May 2024
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From May 2023 to May 2024